ArticleBMC infectious diseases2024
Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Prevalence and Correlates of Dyslipidemia in HIV-Positive Patients at Selected Public Hospitals in Addis Ababa, Ethiopia, 2025.AIDS research and treatment · 2026Article
- High dyslipidemia in people living with HIV in ghana: a cross-sectional analysis of prevalence and associated factors.AIDS research and therapy · 2025Article
- The association between dolutegravir based first-line antiretroviral regimens and dyslipidemia among adults living with HIV on follow-up at health facilities in Hawassa city administration, Sidama region: a cross-sectional study.Atherosclerosis plus · 2025Article
- Hypertension among people living with HIV receiving dolutegravir-based antiretroviral therapy in ethiopia: a cross-sectional study.Scientific reports · 2025Article
- Spectrum and Correlates of Dyslipidemia in People Living with HIV on Dolutegravir-Based Regimen Attending Kabutare Hospital, Southern Rwanda: A Cross-Sectional Study.HIV/AIDS (Auckland, N.Z.) · 2025Article
- Atherogenic Index of Plasma and High-Sensitivity C-Reactive Protein Levels Among People Living With HIV on Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy and Their Correlations to CD4 Cell Counts.AIDS research and treatment · 2025Article
- Article
- Prevalence and determinants of metabolic syndrome among adults living with HIV on first-line antiretroviral treatment in southern Ethiopia: a cross-sectional study.Therapeutic advances in chronic disease · 2025Article
- Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study.AIDS research and treatment · 2025Article
- Association of high serum aspartate transaminase to high density lipoprotein-cholesterol ratio with probable dementia among people living with HIV on antiretroviral therapy in Southwestern Uganda.SAGE open medicine · 2025Article
- Weight and Lipid Levels in People Living With HIV and Initiating a Dolutegravir-Based Regimen in a Resource Limited Setting: A Prospective Study.AIDS research and treatment · 2024Article
- Prevalence of Hyperlipidemia and Associated Factors Among People Living With HIV Attending Care at Rugazi Health Center IV, Rubirizi District South-Western Uganda.Journal of the International Association of Providers of AIDS CareArticle
- Dyslipidemia and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Central Uganda.Journal of the International Association of Providers of AIDS CareArticle
- Association Between High Serum Alanine Aminotransferase to High Density Lipoprotein Cholesterol Ratio and Metabolic Syndrome among People Living with HIV on Dolutegravir-Based ART in South-Western Uganda.Journal of the International Association of Providers of AIDS CareArticle
- Changes in Metabolic Parameters After Switching From Efavirenz to Dolutegravir-Based Regimen: A Cohort Study in Thai People Living With HIV.Journal of the International Association of Providers of AIDS CareArticle
- Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundUnderstanding the burden of dyslipidemia and its associated factors among adult people living with HIV on dolutegravir (DTG) based anti-retroviral therapy (ART) is critical to provide clinical guidance and risk reduction strategies in our setting.
methodsWe conducted a cross-sectional study on adult people living with HIV on DTG based ART between July and August 2022 at Mengo Hospital, a private not for profit missionary hospital owned by the Church of Uganda. Dyslipidemia was defined as: Total cholesterol (TC) ≥ 5.2 mmol/l, or high-density lipoprotein (HDL) < 1 mmol/l for men and < 1.3 mmol/l for women, or triglycerides (TG) ≥ 1.7 mmol/l, and low-density lipoprotein (LDL) ≥ 3.4 mmol/l. A participant was considered to have dyslipidemia if they had any of the lipid profile parameters in the above ranges. Socio-demographic information, clinical data and behavioral characteristics were collected. Fasting lipid profile and fasting blood glucose levels were also measured. Bivariate and multivariate analyses were done using a generalized linear model regression of the Poisson family with a log link (modified Poisson) using robust standard errors since the prevalence of dyslipidemia was more than 10%. Adjusted prevalence ratios (PR) were reported with their 95% confidence intervals (CI). A p-value of less than 0.05 was considered statistically significant.
resultsA total of 341 participants were included. The prevalence of dyslipidemia was 78.0%, (95%CI:73.3-82.1). The highest prevalence was for low HDL (72.1%, 95%CI 67.1-76.7) followed by high TG (20.2%, 95%CI: 16.3-24.9), high TC (12.0%, 95%CI: 9.0-15.9) and high LDL (6.5%, 95%CI: 4.3-9.6). Female sex (aPR:1.55, 95%CI: 1.32-1.84, p < 0.001) and previous use of protease inhibitor (PI) based ART regimen (aPR:1.26, 95%CI: 1.04-1.53, p = 0.018) were significantly associated with dyslipidemia.
conclusionWe demonstrate that the prevalence of dyslipidemia is very high as it was present in more than three quarters of the study participants. Female sex and previous use of PI based ART regimen were significantly associated with dyslipidemia. Management of dyslipidemia should be integrated in the HIV treatment package and we recommend further inquiry into the temporal relationship between dyslipidemia and DTG among ART patients, if any.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.